VolitionRx to use Expedeon’ Biotin Technology in its Epigenetic Research Kits

In-licensing deal between VolitionRx and UK-based Expedeon helps drive development of novel cancer diagnostics VolitionRx Limited (OTC: VNRX), a life sciences company focused on the development of blood-based diagnostic tests, has signed a non-exclusive in-licensing agreement with Expedeon, a specialist provider of bioconjugation systems, based in Cambridge, UK. Under the agreement, Expedeon will supply its…